VF
FATE icon

Virtu Financial’s Fate Therapeutics FATE Stock Holding History

Virtu Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-76,561
Closed -$92K – 1803
2026
Q1 		$92K Buy
76,561
+7,690
+11% +$9.36K ﹤0.01% 1209
2025
Q4 		$68K Buy
+68,871
New +$82.7K ﹤0.01% 1268
2025
Q3 		– Sell
-100,879
Closed -$113K – 1655
2025
Q2 		$113K Buy
+100,879
New +$117K 0.01% 1026
2023
Q1 		– Sell
-14,594
Closed -$147K – 1677
2022
Q4 		$147K Buy
14,594
+1,921
+15% +$36.1K 0.02% 825
2022
Q3 		$284K Buy
+12,673
New +$366K 0.03% 679
2021
Q2 		– Sell
-11,759
Closed -$970K – 1678
2021
Q1 		$970K Buy
+11,759
New +$1.13M 0.07% 264
2018
Q2 		– Sell
-16,521
Closed -$161K – 2116
2018
Q1 		$161K Sell
16,521
-1,730
-9% -$16.6K 0.01% 1443
2017
Q4 		$112K Sell
18,251
-242
-1% -$1.08K 0.01% 1878
2017
Q3 		$73K Buy
+18,493
New +$62.9K ﹤0.01% 2151

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Virtu Financial's FATE Position: Q2 2026 in Review

Virtu Financial sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 76,561 shares — an estimated $92K sold.

Virtu Financial first reported a position in FATE in Q3 2017 and held it in 9 quarters. The position peaked at $970K in Q1 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Virtu Financial reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 76,561 Fate Therapeutics shares in Q2 2026, an estimated $92K.
  • Virtu Financial first reported a position in Fate Therapeutics in Q3 2017 and held it in 9 quarters.
  • Virtu Financial's Fate Therapeutics position peaked at $970K in Q1 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.